A Study of SHR6508 in Secondary Hyperparathyroidism

See also
Status	Clinical Trial	Phase
Completed	`NCT02549417` - Phase 3 Study of KHK7580	Phase 3
Completed	`NCT02549404` - Phase 3 Study of KHK7580	Phase 3
Completed	`NCT02549391` - Phase 3 Study of KHK7580	Phase 2/Phase 3
Not yet recruiting	`NCT02536287` - Comparison of Total Parathyroidectomy With and Without Autotransplantation	Phase 3
Active, not recruiting	`NCT03023748` - Intravenous Paricalcitol in Chronic Hemodialysis Patients	Phase 4
Withdrawn	`NCT01426724` - Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease	N/A
Completed	`NCT01101113` - Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level	Phase 4
Completed	`NCT01220050` - Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism	Phase 2
Completed	`NCT00537979` - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis	Phase 4
Completed	`NCT00379899` - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4
Completed	`NCT00431496` - A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)	Phase 4
Completed	`NCT00073710` - Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium	Phase 4
Completed	`NCT00117052` - SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism	Phase 3
Completed	`NCT03626948` - SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis	Phase 3
Completed	`NCT01382212` - A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis	Phase 3
Completed	`NCT01224782` - Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)	N/A
Completed	`NCT01219855` - Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)	Phase 2/Phase 3
Completed	`NCT00999037` - FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease	N/A
Completed	`NCT00990704` - Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism	Phase 2
Completed	`NCT00742716` - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease	Phase 2

NCT number	NCT05663411
Study type	Interventional
Source	Shanghai Hengrui Pharmaceutical Co., Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	February 24, 2023
Completion date	November 30, 2023

A Study of SHR6508 in Secondary Hyperparathyroidism

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms